Literature DB >> 28863467

Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.

Shashank Gupta1, Laurene Cheung1, Supriya Pokkali1, Kathryn Winglee1, Haidan Guo1, John R Murphy1,2, William R Bishai1.   

Abstract

Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Denileukin diftitox recombinant fusion protein toxin; Host-directed therapy; Immunotherapy; Tuberculosis

Mesh：

Substances：

Year:  2017        PMID： 28863467      PMCID： PMC5853937          DOI： 10.1093/infdis/jix208

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

Authors:  Francine M Foss; Nelida Sjak-Shie; Andre Goy; Eric Jacobsen; Ranjana Advani; Mitchell R Smith; Rami Komrokji; Kelly Pendergrass; Vanessa Bolejack
Journal:  Leuk Lymphoma       Date:  2013-01-29

2.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Authors:  Shashank Gupta; Sandeep Tyagi; Deepak V Almeida; Mariama C Maiga; Nicole C Ammerman; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

3.  Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.

Authors:  Taku Fujimura; Sabine Ring; Viktor Umansky; Karsten Mahnke; Alexander H Enk
Journal:  J Invest Dermatol       Date:  2011-12-22       Impact factor: 8.551

4.  Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12.

Authors:  Shahin Shafiani; Crystal Dinh; James M Ertelt; Albanus O Moguche; Imran Siddiqui; Kate S Smigiel; Pawan Sharma; Daniel J Campbell; Sing Sing Way; Kevin B Urdahl
Journal:  Immunity       Date:  2013-06-20       Impact factor: 31.745

5.  Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.

Authors:  Karsten Mahnke; Kurt Schönfeld; Sabine Fondel; Sabine Ring; Svetlana Karakhanova; Katharina Wiedemeyer; Tanja Bedke; Theron Scott Johnson; Volker Storn; Sonja Schallenberg; Alexander Herrmann Enk
Journal:  Int J Cancer       Date:  2007-06-15       Impact factor: 7.396

6.  A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).

Authors:  Elizabeth Atchison; John Eklund; Brenda Martone; Lili Wang; Adi Gidron; Gary Macvicar; Alfred Rademaker; Charles Goolsby; Laura Marszalek; James Kozlowski; Norm Smith; Timothy M Kuzel
Journal:  J Immunother       Date:  2010-09       Impact factor: 4.456

7.  Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.

Authors:  T Kiyokawa; D P Williams; C E Snider; T B Strom; J R Murphy
Journal:  Protein Eng       Date:  1991-04

8.  IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Authors:  Mary T Litzinger; Romaine Fernando; Tyler J Curiel; Douglas W Grosenbach; Jeffrey Schlom; Claudia Palena
Journal:  Blood       Date:  2007-07-06       Impact factor: 22.113

9.  Therapeutic enhancement of protective immunity during experimental leishmaniasis.

Authors:  Senad Divanovic; Aurelien Trompette; Jamie I Ashworth; Marepalli B Rao; Christopher L Karp
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

10.  Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.

Authors:  Sucheta Telang; Mary Ann Rasku; Amy L Clem; Karen Carter; Alden C Klarer; Wesley R Badger; Rebecca A Milam; Shesh N Rai; Jianmin Pan; Hana Gragg; Brian F Clem; Kelly M McMasters; Donald M Miller; Jason Chesney
Journal:  BMC Cancer       Date:  2011-12-13       Impact factor: 4.430
View more
  15 in total

1.  Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.

Authors:  Shashank Gupta; Stefanie Krug; Supriya Pokkali; Tomas Leanderson; John T Isaacs; Geetha Srikrishna; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

Review 2.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

3.  Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.

Authors:  Sadiya Parveen; Shichun Lun; Michael E Urbanowski; Mitchell Cardin; Jessica Shen; John R Murphy; William R Bishai
Journal:  J Infect Dis       Date:  2021-12-01       Impact factor: 5.226

Review 4.  Proteomics of Mycobacterium Infection: Moving towards a Better Understanding of Pathogen-Driven Immunomodulation.

Authors:  Eik Hoffmann; Arnaud Machelart; Ok-Ryul Song; Priscille Brodin
Journal:  Front Immunol       Date:  2018-01-30       Impact factor: 7.561

5.  Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.

Authors:  Divakar Sharma; Yogesh K Dhuriya; Nirmala Deo; Deepa Bisht
Journal:  Front Microbiol       Date:  2017-12-11       Impact factor: 5.640

Review 6.  Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection.

Authors:  Alanna M Kelly; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

7.  Human Monocytic Suppressive Cells Promote Replication of Mycobacterium tuberculosis and Alter Stability of in vitro Generated Granulomas.

Authors:  Neha Agrawal; Ioana Streata; Gang Pei; January Weiner; Leigh Kotze; Silke Bandermann; Laura Lozza; Gerhard Walzl; Nelita du Plessis; Mihai Ioana; Stefan H E Kaufmann; Anca Dorhoi
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

Review 8.  Drug Repurposing for the Treatment of Bacterial and Fungal Infections.

Authors:  Andrea Miró-Canturri; Rafael Ayerbe-Algaba; Younes Smani
Journal:  Front Microbiol       Date:  2019-01-28       Impact factor: 5.640

Review 9.  The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis.

Authors:  Tandeka Magcwebeba; Anca Dorhoi; Nelita du Plessis
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

Review 10.  Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.

Authors:  Rodrigo Abreu; Pramod Giri; Fred Quinn
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.